Invesco (IVZ)
NYSEFinancialsAsset ManagementSnapshot 2026-09-04
$33.07+1.10%
Close 2026-09-04 · 1-day change
NYSEFinancialsAsset ManagementSnapshot 2026-09-04
Broken: Primary pillar broken — EPS growth to $2.03 in 2026: FY26 EPS guide $0.71 vs $2.03 target.
Invesco grows assets with $22 billion net inflows in 2026-Q1. It buys back $40 million of shares to reward owners. The company pays down $500 million debt and raises dividends. Earnings per share are expected to rise to $2.03 in 2026.
New ETFs from BlackRock and State Street threaten Invesco's market share. Fee pressure on ETFs may hurt growth. Revenue is expected to shrink about 11% next year. Earnings missed estimates in Q1 2026.
The price is about 13% below our fair value near $31. Analysts expect revenue to fall about 11% next year. Our fair value is slightly above the Street median.
Breaks if: No significant debt reduction or dividend raise in 2026
Breaks if: EPS guidance falls below $1.80 for 2026
Breaks if: Net inflows fall below $15 billion in any quarter
Breaks if: Buybacks drop below $20 million in any quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable management scenario with a focus on long-term growth. The current thesis reflects a cautious outlook due to recent earnings misses, despite some positive trends in organic growth and share repurchases.
The market appears to have priced in a level of stability, as indicated by a low expectations gap. However, IVZ is considered expensive compared to its peers, suggesting that investors may be expecting strong performance moving forward.
Fundamentals are likely to remain under pressure in the near term due to recent weak financial performance. However, management's focus on organic growth and capital allocation may support a gradual recovery if executed effectively.
The thesis hinges on the performance of sector bellwethers like BLK, BX, and KKR, which could influence IVZ's trajectory. Additionally, guidance changes in the next earnings call could significantly impact investor sentiment.
Overall, IVZ's long-term thesis is shaped by stable management and ongoing efforts to improve financial health, but it faces significant risks from sector performance and guidance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Recent growth in loan originations strengthens the balance sheet and capital deployment. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.